CVS Health (CVS) IV elevated as shares near three-year low into Q3
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
CVS Health (CVS) PT Lowered to $76 at Jefferies Following 3Q
November 7, 2017 8:24 AM ESTJefferies lowered its price target on CVS Health (NYSE: CVS) to $76.00 (from $86.00) while maintaining a Hold rating. CVS reported Q3 EPS of $1.50 that beat consensus by $0.02. Similar to the last few quarters, SSS revs were pressured by weakness in front-end sales and the... More
